Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Scancell Holdings ( (GB:SCLP) ) has provided an announcement.
Scancell Holdings, a UK-listed clinical-stage biotech focused on cancer immunotherapies, is advancing a portfolio that includes its lead DNA ImmunoBody candidate iSCIB1+ for melanoma, the Moditope-derived peptide vaccine Modi-1 in solid tumours, and early-stage GlyMab antibodies targeting tumour-specific glycans. The company aims to deliver off-the-shelf, durable immune responses and has already partnered with Genmab on two GlyMab assets.
The company has initiated a chief financial officer transition, appointing seasoned pharma and biotech executive David Schilansky as financial advisor with plans to make him interim CFO later in April as current CFO Sath Nirmalananthan departs. Schilansky’s track record in leading major biotech IPOs and strategic financings is expected to support Scancell’s Phase 3 advancement of iSCIB1+, ongoing funding and partnering efforts, and potential exploration of a future US listing, while a global search for a permanent CFO is under way.
The most recent analyst rating on (GB:SCLP) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Scancell Holdings stock, see the GB:SCLP Stock Forecast page.
Spark’s Take on SCLP Stock
According to Spark, TipRanks’ AI Analyst, SCLP is a Neutral.
The score is held back primarily by weak financials (losses, negative equity, and ongoing cash burn), partially offset by encouraging earnings-call catalysts (IND clearance and Phase III pathway) and strong technical momentum. Valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on SCLP stock, click here.
More about Scancell Holdings
Scancell Holdings is a clinical-stage biotechnology company developing off-the-shelf active immunotherapies designed to induce durable, tumour-specific immune responses for cancer treatment. Its lead DNA ImmunoBody candidate, iSCIB1+, has shown clinically meaningful benefit in melanoma, while peptide immunotherapy Modi-1 is being tested in a Phase 2 trial across multiple solid tumours, and its GlyMab subsidiary is advancing a pipeline of anti-glycan antibodies, including assets licensed to Genmab.
Average Trading Volume: 1,487,750
Technical Sentiment Signal: Sell
Current Market Cap: £116.8M
For detailed information about SCLP stock, go to TipRanks’ Stock Analysis page.